InMed Pharmaceuticals Income Statement (2019-2026) | INM

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.27M0.60M0.51M0.32M0.47M1.03M2.31M0.90M1.24M1.17M1.28M1.26M1.11M1.26M1.30M1.12M0.82M
Cost of Revenue (Quarter)
0.15M0.13M0.27M0.24M0.34M0.84M1.32M0.88M0.92M0.88M0.82M0.77M0.65M1.09M0.73M0.72M0.64M
Gross Profit (Quarter)
0.11M0.18M0.25M-0.49M0.13M0.19M1.57M0.02M0.32M0.29M0.47M0.49M0.46M0.18M0.58M0.40M0.18M
Operating items
Research & Development (Quarter)
1.72M1.49M2.54M1.75M1.50M1.38M0.03M0.02M3.63M1.29M0.61M0.66M0.66M0.70M0.90M0.43M0.61M0.58M0.63M1.02M
Selling, General & Administrative (Quarter)
7.29M1.37M1.84M1.92M1.74M1.56M1.46M1.41M1.41M1.30M1.36M1.37M1.76M1.49M1.72M1.58M2.40M1.53M1.62M1.74M
Restructuring Costs (Quarter)
0.04M0.03M-0.08M0.01M0.01M0.02M
Other Operating Expenses (Quarter)
-5.70M0.03M0.05M0.05M3.53M0.15M0.81M0.88M-2.90M0.10M-0.01M0.09M0.06M0.04M0.10M0.07M0.03M0.11M0.04M0.07M
Operating Expenses (Quarter)
3.31M2.89M4.42M3.72M6.77M3.08M2.35M2.34M2.06M2.69M1.97M2.13M2.50M2.23M2.71M2.08M3.04M2.22M2.29M2.84M
Operating Income (Quarter)
-4.31M-3.54M-6.52M-3.58M-2.21M-2.15M-0.49M-2.67M-1.64M-1.84M-2.03M-1.73M-2.25M-1.91M-2.47M-1.82M-2.10M
EBIT (Quarter)
-2.97M-4.31M-3.54M-6.52M-3.58M-2.21M-2.15M-0.49M-2.67M-1.64M-1.84M-2.03M-1.73M-2.25M-1.91M-2.47M-1.82M-2.10M-2.36M
Non-operating items
Interest & Investment Income (Quarter)
0.00M0.01M0.03M0.03M0.03M0.07M0.12M0.16M0.15M0.14M0.17M0.12M0.10M0.06M0.03M0.02M0.05M0.09M0.07M0.05M
Other Non Operating Income (Quarter)
-0.19M-0.08M0.00M0.03M-0.07M-0.10M0.02M-0.00M0.03M-0.05M0.06M-0.05M-0.03M0.02M-0.05M-0.02M0.02M-0.06M0.02M-0.02M
Non Operating Income (Quarter)
0.16M0.15M0.12M0.53M
Net income details
EBT (Quarter)
-2.97M-4.28M-3.48M-7.87M-3.50M-2.10M-2.00M-0.34M-2.54M-1.48M-1.72M-1.93M-1.68M-2.58M-2.07M-1.31M-1.73M-2.03M-2.79M
Tax Provisions (Quarter)
0.01M
Profit After Tax (Quarter)
-3.26M-2.97M-4.28M-3.48M-7.87M-3.51M-2.10M-2.00M-0.30M-2.54M-1.48M-1.72M-2.00M-1.68M-2.58M-2.12M-1.80M-1.73M-2.03M-2.97M
Income from Non-Controlling Interests (Quarter)
0.35M0.02M
Income from Continuing Operations (Quarter)
-2.97M-4.28M-3.48M-7.87M-3.51M-2.10M-2.00M-0.34M-2.54M-1.48M-1.72M-1.93M-1.68M-2.58M-2.07M-1.31M-1.73M-2.03M-2.79M
Consolidated Net Income (Quarter)
-2.97M-4.28M-3.48M-7.87M-3.51M-2.10M-2.00M-0.34M-2.54M-1.48M-1.72M-1.93M-1.68M-2.58M-0.05M-1.31M-1.73M-2.03M-0.17M
Income towards Parent Company (Quarter)
-2.97M-4.28M-3.48M-7.87M-3.51M-2.10M-2.00M-0.34M-2.54M-1.48M-1.72M-1.93M-1.68M-2.58M-0.05M-1.31M-1.73M-2.03M-0.17M
Net Income towards Common Stockholders (Quarter)
-2.97M-4.28M-3.48M-7.87M-3.51M-2.10M-2.00M-0.34M-2.54M-1.48M-1.72M-1.93M-1.68M-2.58M-0.05M-1.31M-1.73M-2.03M-0.17M
Additional items
EPS (Basic) (Quarter)
-123.33-154.64-122.80-280.66-81.10-18.24-12.00-2.75-15.24-3.71-3.58-5.07-2.71-3.64-0.05-1.34-0.44-0.51-0.04
EPS (Diluted) (Quarter)
-123.33-154.64-122.80-280.66-81.10-18.24-12.00-2.75-15.24-3.71-3.58-5.07-2.71-3.64-0.05-1.34-0.44-0.51-0.04
Shares Outstanding (Quarter)
0.01M0.02M0.03M0.03M0.03M0.04M0.12M0.17M0.12M0.17M0.40M0.48M0.38M0.62M0.71M1.10M0.98M3.95M3.95M4.05M
Shares Outstanding (Diluted) (Quarter)
0.01M0.02M0.03M0.03M0.03M0.04M0.12M0.17M0.12M0.17M0.40M0.48M0.38M0.62M0.71M1.10M0.98M3.95M3.95M4.05M
Shares Outstanding (Entity) (Quarter)
0.02M0.03M0.12M0.17M
EBITDA (Quarter)
-2.97M-4.31M-3.54M-6.52M-3.58M-2.21M-2.15M-0.49M-2.67M-1.64M-1.84M-2.03M-1.73M-2.25M-1.91M-2.47M-1.82M-2.10M-2.36M
Interest Expenses (Quarter)
13.97M18.68M0.54M0.61M0.16M-0.09M1.15M1.25M1.10M-0.16M0.22M1.01M0.90M0.02M0.77M0.02M0.43M
Tax Rate (Quarter)
-0.19%